title: A case of penile squamous cell carcinoma treated with a combination of antiepidermal growth factor receptor antibody and chemotherapy.
abstract: Our previous study showed that the features of epidermal growth factor receptor (EGFR)-RAS signaling in penile squamous cell carcinoma (SCC) suggested potential benefits of anti-EGFR monoclonal antibodies (mAbs) for penile SCC. Here, we report, for the first time, a combination of nimotuzumab (an EGFR mAb) with chemotherapy that resulted in a partial response in a 44-year-old patient with penile SCC, who developed bilateral inguinal node metastasis after primary partial penile amputation. The literature of case reports of anti-EGFR mAbs in penile SCC was also reviewed.
authors.affiliation: Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Men
authors.forename: Hong-Feng
authors.initials: HF
authors.lastname: Gou
authors.forename: Meng
authors.initials: M
authors.lastname: Qiu
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: He
authors.forename: Ke
authors.initials: K
authors.lastname: Cheng
authors.forename: Ye
authors.initials: Y
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Ge
authors.forename: Ji-Yan
authors.initials: JY
authors.lastname: Liu
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D066246:ErbB Receptors / Q000276:immunology*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D010412:Penile Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C501466:nimotuzumab; D066246:ErbB Receptors; D017239:Paclitaxel; D002945:Cisplatin